C-Suite

CVS Health filed a similar lawsuit last month.

But employers surveyed in February and March were more aware of TrumpRx than of weight-loss drug sites like Ro.

Of the 40 states with available data, SmartAsset reports, all but 11 saw advisors' median income increase.

As medical and pharmacy expenses climb, large employers are adjusting plan design, limiting drug spending growth, and expanding targeted support like caregiving and financial wellness benefits.

According to the report, employer spending on GLP-1 drugs doubled in a single year, rising from $11 to $24 per member per month. GLP-1s now account for 10.5% of all prescription drug claims, up from 6.9% in 2023.

This increase reflects the convergence of several powerful forces reshaping the health care landscape, according to a PWC report.